– USA, CA – ESCAPE Bio Inc., a clinical-stage company developing novel, precisely targeted therapeutics for genetic neurodegenerative diseases, announced the appointments of Ed Owens and Scott Morrison to its Board of Directors.
“Ed brings an unparalleled perspective of our industry based on over four decades of outstanding performance investing in healthcare companies,” said CEO, Julie Anne Smith. “We are delighted to have his insight on business fundamentals, industry insights and shareholder value.”
“Scott is a well-respected industry leader who brings over 40 years of financial experience helping life science companies grow from start-up, through initial product launch, to global expansion,” said Tony Rimac, CFO. “We look forward to his financial acumen and corporate insight as we advance our pipeline of Precision Neurology medicines.”
About Edwards Owens
Mr. Owens is a retired partner of Wellington Management, where he was a portfolio manager and global industry analyst from 1974 to 2012. At Wellington, he was the founding manager of the Vanguard Health Care Fund, which during his 28-year tenure was the best performing US mutual fund and became the largest industry sector fund.
Mr. Owens serves on the board of directors of Ironwood Pharmaceuticals and Stealth BioTherapeutics. He was previously on the boards of the Marine Biological Laboratory, the Wellington Management Foundation, and the UVa College Foundation. He served in the US Navy as a nuclear submarine officer.
He holds a B.S. in Physics from the University of Virginia and an M.B.A. from Harvard Business School.
About Scott Morrison
Mr. Morrison began serving life sciences companies in 1980 and was a partner at Ernst & Young from 1996 until his retirement in 2015. He served as EY’s U.S. Life Sciences Leader from 1996 to 2015. During his tenure at EY, he worked on hundreds of public and private financings, M&A transactions, and corporate collaborations.
Mr. Morrison served on the Board of Directors and chairs the Audit Committee of Audentes, Inc. (through its sale to Astellas in January 2020), Corvus Pharmaceuticals, Global Blood Therapeutics, and Ideaya Biosciences. He also serves as a member of the Compensation Committee for GBT and Corvus and is a member of the GBT’s Commercial Committee. Mr. Morrison has also served as a director on several life sciences industry boards including the Biotechnology Innovation Organization ECS board, the Bay Area Biosciences Board, the Life Sciences Foundation, and the Biotechnology Institute. Mr. Morrison was awarded the CLSA Pantheon 2016 Life Sciences Leadership Award.
Mr. Morrison holds a B.S. in Business Administration from the Haas School at the University of California, Berkeley and is a Certified Public Accountant.
About ESCAPE Bio
ESCAPE Bio is a clinical-stage, a privately-held biopharmaceutical company developing novel, precisely targeted therapeutics for genetically defined neurodegenerative diseases. ESB1609 is in a Phase 1 multiple ascending dose study in healthy volunteers. ESCAPE has advanced a mutant-selective LRRK2 G2019S kinase inhibitor for Parkinson’s Disease patients to IND-enabling studies. A pharmacologic structure corrector of Alzheimer’s patients carrying the ApoE4 risk allele is in Discovery.
For more information: https://www.escapebio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
